US75629V1044
US75629V1044
Recursion Pharmaceuticals, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 74.256.000 | 58.488.000 | 27.0% |
| Cost of Revenue | 70.953.000 | 45.238.000 | 56.8% |
| Gross Profit | 3.303.000 | 13.250.000 | 75.1% |
| 651.435.000 | 492.254.000 | 32.3% | |
| Operating Income | -648.132.000 | -479.004.000 | 35.3% |
| Pretax Income | -644.895.000 | -464.788.000 | 38.8% |
| Net Income Common Stockholders | -644.759.000 | -463.661.000 | 39.1% |
| -- | -- | -- | |
| -- | -- | -- |